Susanna L den Boer1, M Lennie van Osch-Gevers1, Gijs van Ingen1, Gideon J du Marchie Sarvaas2, Gabriëlle G van Iperen3, Ronald B Tanke4, Ad P C M Backx5, Arend D J Ten Harkel6, Willem A Helbing1, Tammo Delhaas7, Ad J J C Bogers8, Lukas A J Rammeloo9, Michiel Dalinghaus10. 1. Department of Pediatric Cardiology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam. 2. Department of Pediatric Cardiology, Beatrix Children's Hospital, University Medical Center Groningen, Groningen. 3. Department of Pediatric Cardiology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht. 4. Department of Pediatric Cardiology, Radboud University Medical Center, Nijmegen. 5. Department of Pediatric Cardiology, Emma Children's Hospital, Academic Medical Center, Amsterdam. 6. Department of Pediatric Cardiology, Leiden University Medical Center, Leiden. 7. Department of Pediatric Cardiology, Maastricht University Medical Center, Maastricht. 8. Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam. 9. Department of Pediatric Cardiology, Free University Medical Center, Amsterdam, The Netherlands. 10. Department of Pediatric Cardiology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam. Electronic address: m.dalinghaus@erasmusmc.nl.
Abstract
BACKGROUND: The policy for listing and transplant for children with dilated cardiomyopathy (DCM) in The Netherlands has been conservative because of low donor availability. The effects of this policy on outcome are reported. METHODS: This was a multicenter, nationwide study performed in 148 children with DCM. The primary outcome was death or heart transplant. RESULTS: Overall, 43 patients (29%) died or were transplanted. Within 1 year of diagnosis, 21 patients died, and only 4 underwent transplantation (3 on mechanical circulatory support). The 1-year survival was 85% (95% confidence interval [CI] = 79-91), and 5-year survival was 84% (95% CI = 78-90). Transplantation-free survival at 1 year was 82% (95% CI = 75-88) and at 5 years was 72% (95% CI = 64-80). Within 1 year of diagnosis, with death as the main end-point (21 of 25, 84%), intensive care unit admission (hazard ratio = 2.6, p = 0.05) and mechanical circulatory support (hazard ratio = 3.2, p = 0.03) were risk factors (multivariable Cox analysis); inotropic support was longer in patients reaching an end-point. At >1 year after diagnosis, with transplantation as the main end-point (15 of 18, 83%), age >6 years (hazard ratio = 6.1, p = 0.02) was a risk factor. There were 56 (38%) children who recovered, 50% within 1 year of diagnosis. Recovery was associated with younger age; was similar in patients with myocarditis (43%) and idiopathic disease (41%); and was similar in patients initially admitted to the intensive care unit, admitted to the ward, or treated as outpatients. CONCLUSIONS: The transplantation rate in our cohort in the first year was low, with 1-year and 5-year survival rates similar to other cohorts. Our results suggest that a conservative approach to list children for transplantation early after presentation may be justifiable except for patients with prolonged intensive care unit or mechanical circulatory support.
BACKGROUND: The policy for listing and transplant for children with dilated cardiomyopathy (DCM) in The Netherlands has been conservative because of low donor availability. The effects of this policy on outcome are reported. METHODS: This was a multicenter, nationwide study performed in 148 children with DCM. The primary outcome was death or heart transplant. RESULTS: Overall, 43 patients (29%) died or were transplanted. Within 1 year of diagnosis, 21 patients died, and only 4 underwent transplantation (3 on mechanical circulatory support). The 1-year survival was 85% (95% confidence interval [CI] = 79-91), and 5-year survival was 84% (95% CI = 78-90). Transplantation-free survival at 1 year was 82% (95% CI = 75-88) and at 5 years was 72% (95% CI = 64-80). Within 1 year of diagnosis, with death as the main end-point (21 of 25, 84%), intensive care unit admission (hazard ratio = 2.6, p = 0.05) and mechanical circulatory support (hazard ratio = 3.2, p = 0.03) were risk factors (multivariable Cox analysis); inotropic support was longer in patients reaching an end-point. At >1 year after diagnosis, with transplantation as the main end-point (15 of 18, 83%), age >6 years (hazard ratio = 6.1, p = 0.02) was a risk factor. There were 56 (38%) children who recovered, 50% within 1 year of diagnosis. Recovery was associated with younger age; was similar in patients with myocarditis (43%) and idiopathic disease (41%); and was similar in patients initially admitted to the intensive care unit, admitted to the ward, or treated as outpatients. CONCLUSIONS: The transplantation rate in our cohort in the first year was low, with 1-year and 5-year survival rates similar to other cohorts. Our results suggest that a conservative approach to list children for transplantation early after presentation may be justifiable except for patients with prolonged intensive care unit or mechanical circulatory support.
Authors: Teresa M Lee; Daphne T Hsu; Paul Kantor; Jeffrey A Towbin; Stephanie M Ware; Steven D Colan; Wendy K Chung; John L Jefferies; Joseph W Rossano; Chesney D Castleberry; Linda J Addonizio; Ashwin K Lal; Jacqueline M Lamour; Erin M Miller; Philip T Thrush; Jason D Czachor; Hiedy Razoky; Ashley Hill; Steven E Lipshultz Journal: Circ Res Date: 2017-09-15 Impact factor: 17.367
Authors: Rakesh K Singh; Charles E Canter; Ling Shi; Steven D Colan; Debra A Dodd; Melanie D Everitt; Daphne T Hsu; John L Jefferies; Paul F Kantor; Elfriede Pahl; Joseph W Rossano; Jeffrey A Towbin; James D Wilkinson; Steven E Lipshultz Journal: J Am Coll Cardiol Date: 2017-11-28 Impact factor: 24.094
Authors: Susanna L den Boer; Koen F M Joosten; Sandra van den Berg; Ad P C M Backx; Ronald B Tanke; Gideon J du Marchie Sarvaas; Willem A Helbing; Lukas A J Rammeloo; Arend D J ten Harkel; Gabriëlle G van Iperen; Michiel Dalinghaus Journal: Pediatr Cardiol Date: 2015-10-16 Impact factor: 1.655
Authors: Ilse A E Bollen; Marijke van der Meulen; Kyra de Goede; Diederik W D Kuster; Michiel Dalinghaus; Jolanda van der Velden Journal: Front Physiol Date: 2017-12-22 Impact factor: 4.566
Authors: Susanna L den Boer; Daniël H K Flipse; Marijke H van der Meulen; Ad P C M Backx; Gideon J du Marchie Sarvaas; Arend D J Ten Harkel; Gabriëlle G van Iperen; Lukas A J Rammeloo; Ronald B Tanke; Willem A Helbing; Tim Takken; Michiel Dalinghaus Journal: Pediatr Cardiol Date: 2016-12-01 Impact factor: 1.655
Authors: Malindi van der Mheen; Marijke H van der Meulen; Susanna L den Boer; Dayenne J Schreutelkamp; Jan van der Ende; Pieter Fa de Nijs; Johannes Mpj Breur; Ronald B Tanke; Nico A Blom; Lukas Aj Rammeloo; Arend Dj Ten Harkel; Gideon J du Marchie Sarvaas; Elisabeth Mwj Utens; Michiel Dalinghaus Journal: Eur J Cardiovasc Nurs Date: 2019-09-25 Impact factor: 3.908
Authors: Marijke van der Meulen; Susanna den Boer; Gideon J du Marchie Sarvaas; Nico Blom; Arend D J Ten Harkel; Hans M P J Breur; Lukas A J Rammeloo; Ronald Tanke; Ad J J C Bogers; Willem A Helbing; Eric Boersma; Michiel Dalinghaus Journal: ESC Heart Fail Date: 2021-02-05
Authors: Marijke H van der Meulen; Susanna den Boer; Gideon J du Marchie Sarvaas; Nico A Blom; Arend D J Ten Harkel; Hans M P J Breur; Lukas A J Rammeloo; Ronald Tanke; Willem A Helbing; Eric Boersma; Michiel Dalinghaus Journal: Pediatr Cardiol Date: 2019-11-12 Impact factor: 1.655